Navigation Links
Mayo Clinic: Researchers to study body's defense system to find new treatments for Alzheimer's
Date:11/12/2013

JACKSONVILLE, Fla. Researchers at Mayo Clinic in Florida, the University of Florida in Gainesville, and the Institute for Systems Biology in Seattle have received a $7.5 million grant from the National Institutes of Health to take a new and more expanded approach to identifying drug targets to treat and possibly prevent Alzheimer's disease.

VIDEO ALERT: Video resources including an interviewwith Dr. Ertekin-Taner describing the study can be found on the Mayo Clinic News Network.

The investigators are working together to understand the role that innate immunity the body's defense system plays in Alzheimer's disease, a disorder of dementia that is rapidly increasing as the population ages.

The teams are focused on uncovering and manipulating the key molecular players in innate immunity with an ultimate goal of developing novel therapies for Alzheimer's disease, says neurologist and neuroscientist Nilufer Ertekin-Taner, M.D., Ph.D., one of the grant's two principal investigators from Mayo Clinic in Florida. The other is Steven Younkin, M.D., Ph.D.

"When activated, human innate immunity results in inflammation, and previous research on this response to development of Alzheimer's disease has been contradictory because no one has yet looked at the whole picture of this effect over time," says Dr. Ertekin-Taner. "It may be that an initial inflammatory response is beneficial, perhaps even protective, but a lengthy response to toxic proteins acts to kill healthy neurons.

"Our goal is to understand exactly if and when an innate immune response is good, and when it is bad, and to identify drug targets that enhance this protective effect and shut down the destructive side of this inflammation."

To do that, the study's leaders which include Todd Golde, M.D., Ph.D., director for Translational Research in Neurodegenerative Disease at the University of Florida, and Nathan Price, Ph.D., from the Institute for Systems Biology have designed a systems level approach.

"We want to look at all the different components together," Dr. Ertekin-Taner explains. For example, using brain samples of Alzheimer's disease patients from Mayo Clinic's brain bank directed by Dennis Dickson, M.D., and clinical samples from collaborators in Neurology, Dr. Ertekin-Taner and Dr. Younkin will generate biological information. This will include identification of key genes and RNA transcripts involved in the innate immune response to the disease.

Dr. Golde, a former chair of the Department of Neuroscience at Mayo Clinic, will use animal models of Alzheimer's disease to find similar expression data; he will also test findings from the Mayo researchers in the animals. Dr. Price will employ advanced computational methods to synthesize data generated by the teams to identify key molecules involved in this pathway. Dr. Golde will then test these results in the animal models, and see what happens when molecular targets are manipulated with novel agents.

"This grant is a beautiful example of bringing together large data and expertise from different groups into a single goal to really understand key aspects of this important pathway," Dr. Ertekin-Taner says. "We have great hope for such a novel and cutting-edge approach like this, and can't wait to get started."


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: Less-invasive option as effective as esophagus removal in early esophageal cancer
2. Mayo Clinic: Enhanced recovery pathway for gynecologic surgery gets patients back to health faster
3. Mayo Clinic: Preclinical tests may lead to new approach to treat CNS lymphoma
4. Mayo Clinic: Rotavirus vaccine given to newborns in Africa is effective
5. Mayo Clinic: How gold nanoparticles can help fight ovarian cancer
6. Mayo Clinic: Inflammatory bowel disease raises risk of melanoma
7. Mayo Clinic: Scheduled imaging studies provide little help detecting relapse of aggressive lymphoma
8. Mayo Clinic: New multiple myeloma treatment guidelines personalize therapy for patients
9. Mayo Clinic: Skin problems, joint disorders top list of reasons people visit doctors
10. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
11. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer ... started as the Chairman of the Management Committee when IFN was originally formed in ... recruitment of investor/owners and development of the business plan. He became the first ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the celebrated ... Giveaway, with the winning couple announced on Feb. 14, 2017, on Facebook. The ... local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring ...
(Date:2/23/2017)... FL (PRWEB) , ... February 23, 2017 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – will return to the La Gorce Country Club in Miami Beach to ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, ... a raffle. Throughout the month of February, patients who visit Hamlin Dental Group will ... a dinner for two at the Cheesecake Factory. , Tickets are available for ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads ... NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist ... an online directory that recognizes local physicians and dentists who have earned high ratings ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017  The particle counters ... by 2021 from USD 275.9 million in 2016, ... the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... on pharmaceutical R&D, and growth in manufacturing industries ... market growth for particle counters. On the other ...
(Date:2/24/2017)... CHEYENNE, Wyoming , Feb. 24, 2017  Xynomic ... company, today announced that it has acquired exclusive ... a potentially best-in-class innovative HDAC inhibitor targeting hematological ... total of 14 Phase 1 and 2 clinical ... Asia have already been completed, ...
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
Breaking Medicine Technology: